Follistatin 344 Dosage & Reconstitution Guide (Muscle Growth Peptide Explained)

Follistatin 344

Follistatin-344 (FS344) is a form of follistatin studied for its ability to block myostatin and related growth-regulating proteins. Because myostatin normally acts like a “brake” on muscle growth, reducing its activity has been researched as a way to support muscle size and function.

How Follistatin-344 Works

Myostatin Activity ↓ → Muscle-Growth Brake ↓ → Muscle Growth Signaling ↑

Follistatin binds to myostatin and other related proteins that normally limit muscle growth. By reducing this signaling, researchers have studied follistatin as a way to increase muscle size and support muscle function.

Follistatin-344 is not the same thing as a standard muscle-building peptide with an established human injection protocol.

Real human studies have used FS344 gene therapy delivered directly into muscle.

Commercial research-vial Follistatin-344 dosing is based largely on research-community use rather than human clinical injection trials.

Follistatin affects myostatin but can also interact with other growth-regulating proteins.

Follistatin 344 Research Protocol

Research framework:
The fixed microgram ranges below reflect research-community use of commercially available Follistatin-344 peptide vials. Human clinical trials have not established a standard injectable FS344 peptide dose, titration schedule, or cycle length.

1 mg vial → 2.0 mL BAC Water → 1 unit = 5 mcg

Standard Setup

Vial 1 mg

Water 2.0 mL bacteriostatic water

Concentration 0.5 mg/mL

Conversion 1 unit = 5 mcg

Standard Use

Short Cycle

Dose100 mcg daily

Units20 units

Volume0.20 mL

Cycle Length

Short Burst Cycle

Typical Use10–30 days

Advanced Range

Optional Adjustment

Low Range50 mcg (10 units)

Moderate100 mcg (20 units)

Higher Range200 mcg (40 units)

Simple structure
Follistatin is typically used in shorter, aggressive cycles rather than long-term protocols. The goal is short-term signaling impact, not continuous use.

How to Use (Timing, Injection & Structure)

Research FrequencyOnce daily

Research TimingMorning or post-workout

RouteSubcutaneous

Research Cycle Length10–30 days

Injection Notes

Subcutaneous injection

Abdomen, thigh, or upper arm

Use a consistent time daily

Rotate injection sites regularly

Reconstitution & Dosing (1 mg Vial)

Vial1 mg

Water2.0 mL

Concentration0.5 mg/mL

Conversion1 unit = 5 mcg

Dose Reference

10 units = 50 mcg

20 units = 100 mcg

40 units = 200 mcg

Reconstitution Steps

Draw 2.0 mL bacteriostatic water

Inject slowly into the vial

Gently swirl (do not shake)

Allow powder to fully dissolve

Storage & Shelf Life

Lyophilized (Unmixed)

Refrigerated: ~12–24 months

Reconstituted

Refrigerate at 2–8°C

Do not freeze after mixing

Use within 30 days

Research Cycle Length & Time Between Cycles

Short Cycle → Muscle Signaling ↑ → Break → Reassess

Cycle Length10–30 days

Time Off4–8+ weeks

Established Clinical Cycle No

Why reassess?
There is no clinically established Follistatin-344 peptide cycle or required off-period. Shorter research phases are commonly discussed because long-term effects of injectable research-vial FS344 have not been established.

What Human Research Has Studied

FS344 Gene Therapy

Human trials have tested FS344 using gene therapy delivered directly into muscle.

A small Phase 1/2a study in people with Becker muscular dystrophy reported improvements in walking distance in several participants.

Muscle biopsies also showed changes consistent with muscle hypertrophy in some treated subjects.

Another small study in inclusion body myositis also reported improved walking performance after FS344 gene therapy.

Important distinction:
These human studies used gene therapy designed to make the body produce follistatin over time. They do not establish the dosing or effectiveness of injectable Follistatin-344 research vials sold in peptide markets.

Monitoring During Use

Muscle fullness and recovery

Strength progression

Training performance

Injection site tolerance

Research Findings & Potential Effects

Strongly inhibits myostatin signaling

Preclinical research has shown increases in muscle size and strength

Human FS344 gene-therapy studies have reported signs of muscle hypertrophy and improved walking performance in small neuromuscular-disease trials

Effects of injectable research-vial Follistatin-344 in healthy humans have not been established

Research Findings & Potential Effects

Strongly inhibits myostatin signaling

Preclinical research has shown increases in muscle size and strength

Human FS344 gene-therapy studies have reported signs of muscle hypertrophy and improved walking performance in small neuromuscular-disease trials

Effects of injectable research-vial Follistatin-344 in healthy humans have not been established

Follistatin affects activin and other related signaling pathways in addition to myostatin

Long-term effects of injectable Follistatin-344 research vials are not established

Because follistatin can influence activin and reproductive-hormone signaling, broader hormonal effects are possible

Safety findings from FS344 gene-therapy studies should not be assumed to apply to injectable research-vial Follistatin-344

Important Notes

Follistatin-344 is mainly researched for its ability to reduce myostatin signaling.

It also affects activin and other related pathways, so it is not completely myostatin-specific.

Human FS344 research has primarily involved gene therapy, not injected research peptide vials.

There is no established human dose or standardized cycle for commercially available injectable Follistatin-344.

Small human gene-therapy studies have reported encouraging muscle-function results, but this should not be treated as proof that community peptide protocols produce the same outcome.

Product identity and purity are especially important because mislabeled Follistatin-344 products have been documented.

Research Product Quality
Product identity is an important consideration with Follistatin-344. In one published analysis of 17 products sold online as Follistatin-344, only 9 actually contained follistatin. Some of the remaining products contained other growth-related peptides instead. This highlights why labeling alone cannot confirm the identity or purity of a research product.

Important Disclaimer

Follistatin-344 is an investigational research compound and is not FDA-approved as an injectable muscle-building therapy. Human FS344 studies have primarily used gene-therapy approaches in neuromuscular disease and do not establish the safety, dosing, or effectiveness of commercially available research-vial Follistatin-344 protocols. This content is for educational purposes only.

Research & References

Primary Research

• Lee SJ, McPherron AC. Regulation of Myostatin Activity and Muscle Growth. Proceedings of the National Academy of Sciences (PNAS). 2001.
• Haidet AM, Rizo L, Handy C, et al. Long-Term Enhancement of Skeletal Muscle Mass and Strength by Single Gene Administration of Myostatin Inhibitors. Proceedings of the National Academy of Sciences (PNAS). 2008.
• Mendell JR, Sahenk Z, Malik V, et al. A Phase 1/2a Follistatin Gene Therapy Trial for Becker Muscular Dystrophy. Molecular Therapy. 2015.
• Mendell JR, Sahenk Z, Al-Zaidy S, et al. Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes. Molecular Therapy. 2017.

Research Note: Follistatin-344 is one of the best-studied myostatin inhibitors in experimental muscle biology, but nearly all human evidence comes from small AAV gene therapy trials in muscular dystrophy and inclusion body myositis—not from injectable recombinant Follistatin-344 peptide. There are currently no controlled human trials evaluating injectable Follistatin-344 peptide dosing, so protocols circulating online are extrapolated from animal research and gene-therapy studies rather than derived from clinical dosing data.

View Follistatin 344 Guide → Peptide Directory →